Indivior Pharmaceuticals (INDV) Invested Capital (2021 - 2025)

Indivior Pharmaceuticals' Invested Capital history runs 5 years deep, the most recent figure standing at $29.0 million for Q4 2025.

• On a quarterly basis, Invested Capital rose 61.11% year-over-year to $29.0 million in Q4 2025; TTM through Mar 2026 was $65.0 million, a 80.56% increase from a year earlier, with the FY2025 full-year figure at $29.0 million, up 61.11% from the prior year.
• Invested Capital grew to $29.0 million in Q4 2025 per INDV's latest filing, from $18.0 million in the prior quarter.
• Across five years, Invested Capital topped out at $324.0 million in Q4 2022 and bottomed at $18.0 million in Q4 2024.
• The 5-year median for Invested Capital is $23.5 million (2024), against an average of $131.5 million.
• Across the five-year window, Invested Capital plunged 94.21% in 2024 and jumped 61.11% in 2025, its largest moves.
• Year by year, Invested Capital stood at $316.0 million in 2021, then advanced by 2.53% to $324.0 million in 2022, then decreased by 4.01% to $311.0 million in 2023, then plunged by 94.21% to $18.0 million in 2024, then soared by 61.11% to $29.0 million in 2025.
• Per Business Quant, the three latest INDV Invested Capital figures stand at $29.0 million (Q4 2025), $18.0 million (Q3 2025), and $18.0 million (Q2 2025).